Corticosteroid use and risk of orofacial clefts

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 100, Issue 6, 2014, Pages 499-506

  Skuladottir, Hildur ^a,b   Wilcox, Allen J ^c   Ma, Chen ^d   Lammer, Edward J ^e   Rasmussen, Sonja A ^f   Werler, Martha M ^g   Shaw, Gary M ^d   Carmichael, Suzan L ^d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g BOSTON UNIVERSITY   (United States)

Author keywords

Birth defects; Cleft lip and palate; Corticosteroids; Orofacial clefts; Pregnancy

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FOLIC ACID; PREDNISONE; TRIAMCINOLONE;

ARTICLE; BIRTH DEFECT; CHILD; CLEFT LIP PALATE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POPULATION BASED CASE CONTROL STUDY; POPULATION SIZE; PREGNANT WOMAN; PRIORITY JOURNAL; PROGENY; RISK BENEFIT ANALYSIS; RISK FACTOR; TELEPHONE INTERVIEW; BLACK PERSON; CASE CONTROL STUDY; CAUCASIAN; CLEFT LIP; CLEFT PALATE; ENVIRONMENTAL EXPOSURE; ETHNOLOGY; HISPANIC; NEWBORN; ODDS RATIO; PREGNANCY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADRENAL CORTEX HORMONES; AFRICAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CLEFT LIP; CLEFT PALATE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INFANT, NEWBORN; MATERNAL EXPOSURE; ODDS RATIO; PREGNANCY; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84903173010     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23248     Document Type: Article

References (24)

1. Andrade SE, Gurwitz JH, Davis RL, et al. 2004. Prescription drug use in pregnancy. Am J Obstet Gynecol 191:398-407.
2. Carmichael SL, Shaw GM. 1999. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 86:242-244.
3. Carmichael SL, Shaw GM, Ma C, et al. 2007. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 197:585.e581-e587.
4. Chi C, Wang S, Mayon-White R, Wojnarowska F. 2013. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol 149:1274-1280.
5. Czeizel AE, Rockenbauer M. 1997. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 56:335-340.
6. Dixon MJ, Marazita ML, Beaty TH, Murray JC. 2011. Cleft lip and palate: understanding genetic and environmental influences. Nat Rev Genet 12:167-178.
7. Edwards MJ, Agho K, Attia J, et al. 2003. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet A 120A:459-463.
8. Fraser FC, Fainstat TD. 1951. Production of congenital defects in the offspring of pregnant mice treated with cortisone: progress report. Pediatrics 8:527-533.
9. Hviid A, Mølgaard-Nielsen D. 2011. Corticosteroid use during pregnancy and risk of orofacial clefts. Can Med Assoc J 183:796-804.
10. Kallen B, Rydhstroem H, Aberg A. 1999. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 93:392-395.
11. Källén B. 2003. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J 40:624-628.
12. Mossey PA, Little J, Munger RG, et al. 2009. Cleft lip and palate. Lancet 374:1773-1785.
13. Nau H. 1986. Species differences in pharmacokinetics and drug teratogenesis. Environ Health Perspect 70:113-129.
14. Olesen C, Søndergaard C, Thrane N, et al. 2001. Do pregnant women report use of dispensed medications? Epidemiology 12:497-501.
15. Overman RA, Yeh J-Y, Deal CL. 2013. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken) 65:294-298.
16. Piddington R, Herold R, Goldman AS. 1983. Further evidence for a role of arachidonic acid in glucocorticoid teratogenic action in the palate. Proc Soc Exp Biol Med 174:336-342.
17. Pradat P, Robert-Gnansia E, Di Tanna GL et al. 2003. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 67:968-970.
18. Pratt RM, Salomon DS. 1980. Glucocorticoid receptors and cleft palate in mice and man. Prog Clin Biol Res 46:149-167.
19. Rasmussen SA, Olney RS, Holmes LB, et al. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67:193-201.
20. Rodríguez-Pinilla E, Luisa Martínez-Frías M. 1998. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 58:2-5.
21. Skuladottir H, Wilcox A, McConnaughey R, et al. 2013. First-trimester corticosteroid use and the risk of oral clefts in Norway. Submitted.
22. Walker BE, Fraser FC. 1957. The embryology of cortisone-induced cleft palate. J Embryol Exp Morphol 5:201-209.
23. Yoon PW, Rasmussen SA, Lynberg MC, et al. 2001. The National Birth Defects Prevention Study. Public Health Rep 116:32-40.
24. Ziejewski MK, Solomon HM, Stanislaus D, et al. 2012. The potential role for corticosterone in the induction of cleft palate in mice after treatment with a selective nk-1 receptor antagonist, casopitant (gw679769b). Birth Defects Res B Dev Reprod Toxicol 95:54-62.